Voting Rights and Shares Capital of the Company

Rhea-AI Summary

Nanobiotix, a company listed on Euronext Paris and Nasdaq, has released its monthly report on voting rights and shares capital as of July 31, 2024. The report, in compliance with French regulatory requirements, reveals the following key figures:

• Number of Shares Outstanding: 47,426,851
• Total Theoretical Voting Rights: 49,200,912
• Total Exercisable Voting Rights: 49,178,794

This disclosure is part of Nanobiotix's commitment to transparency and adherence to French financial regulations. The company trades under the ticker NBTX on Nasdaq and is part of Euronext Paris Compartment B.

News Market Reaction

+3.06%

1 alert

+3.06% News Effect

On the day this news was published, NBTX gained 3.06%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Aug. 08, 2024 (GLOBE NEWSWIRE) --

Paris, France, August 8, 2024
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, theoretical1	Total voting rights, exercisable2
July 31, 2024	47,426,851	49,200,912	49,178,794

According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com
Media Relations
FR – Ulysse Communication Laurent Wormser + 33 (0)6 13 12 04 04 lwormser@ulysse-communication.com	Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com

 

¹ The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

² The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

Attachment

• 2024-08-08 -- NBTX -- Voting Rights & Shares Capital -- FINAL.pdf

FAQ

What is Nanobiotix's total number of outstanding shares as of July 31, 2024?

As of July 31, 2024, Nanobiotix reported 47,426,851 outstanding shares.

How many total theoretical voting rights does Nanobiotix (NBTX) have?

According to the report, Nanobiotix has 49,200,912 total theoretical voting rights as of July 31, 2024.

What is the difference between Nanobiotix's theoretical and exercisable voting rights?

The difference is 22,118 votes. Nanobiotix reported 49,200,912 theoretical voting rights and 49,178,794 exercisable voting rights as of July 31, 2024.

On which stock exchanges is Nanobiotix (NBTX) listed?

Nanobiotix is dual-listed on Euronext Paris and Nasdaq.